Title : Adding Concurrent Chemotherapy Significantly Improves the Survival of Stage II-IVb Nasopharyngeal Carcinoma Patients Treated With Concurrent Anti-EGFR Agents.

Pub. Date : 2021

PMID : 34976847






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Results: Compared with concurrent anti-EGFR agents alone, combining concurrent cisplatin and anti-EGFR agents significantly improved the OS (5-year 94.7% versus 84.3%, P=0.012) and PFS (5-year 82.0% versus 71.7%, P=0.039) of NPC patients with more severe hematologic toxicity and mucositis. Cisplatin epidermal growth factor receptor Homo sapiens